Table 3.
Article | Study Design | Population | Outcome Measures |
---|---|---|---|
Esterhuizen, K. et al. (2017) [80] | In vitro study | N/A | Role of HN against oxidative stress, apoptosis, and inflammatory response |
Bachar, A.R. et al. (2010) [82] | In vitro study | N/A | HN attenuates inflammation and macrophage infiltration, reduces in vitro production of IL-6, IL-1β, and TNF-α |
Nashine, S. et al. (2022) [94] | In vivo study | AMD patients AMD RPE transmitochondrial cybrid cells |
Treatment with HNG can reduce plasma levels of inflammation-associated marker protein. In AMD RPE cybrid cells, treatment with HNG reduced CD62E/E-Selectin, CD62P/P-Selectin, ICAM-1, TNF-α, MIP-1α, IFN–γ, IL-1β, IL-13. and IL-17A |
Conte, M. et al. (2021) [89] | In vivo study | Patients with T2D and AD | Plasma levels of fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), humanin, and mitochondrial stress-related mitokines |
Conte, M. et al. (2019) [30] | In vivo study | Human | Aging; longevity; plasma levels of different mitokines |
Merry, T.L. et al. (2020) [95] | In vivo study | Human | Plasma humanin levels in long-lived subjects |